The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 6 November 2006 doi:10.1084/jem.20061097
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 12, 2639-2648
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lappas, C. M.
Right arrow Articles by Linden, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lappas, C. M.
Right arrow Articles by Linden, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation

Courtney M. Lappas1, Yuan-Ji Day2, Melissa A. Marshall2, Victor H. Engelhard3, and Joel Linden1,2

1 Department of Pharmacology, 2 Department of Medicine, and 3 Department of Microbiology, University of Virginia, Charlottesville, VA 2290

CORRESPONDENCE Joel Linden: jlinden{at}virginia.edu

Ischemia reperfusion injury results from tissue damage during ischemia and ongoing inflammation and injury during reperfusion. Liver reperfusion injury is reduced by lymphocyte depletion or activation of adenosine A2A receptors (A2ARs) with the selective agonist 4- {3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]- prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester (ATL146e). We show that NKT cells are stimulated to produce interferon (IFN)-{gamma} by 2 h after the initiation of reperfusion, and the use of antibodies to deplete NK1.1-positive cells (NK and NKT) or to block CD1d-mediated glycolipid presentation to NKT cells replicates, but is not additive to, the protection afforded by ATL146e, as assessed by serum alanine aminotransferase elevation, histological necrosis, neutrophil accumulation, and serum IFN-{gamma} elevation. Reduced reperfusion injury observed in RAG-1 knockout (KO) mice is restored to the wild-type (WT) level by adoptive transfer of NKT cells purified from WT or A2AR KO mice but not IFN-{gamma} KO mice. Additionally, animals with transferred A2AR–/– NKT cells are not protected from hepatic reperfusion injury by ATL146e. In vitro, ATL146e potently inhibits both anti-CD3 and {alpha}-galactosylceramide–triggered production of IFN-{gamma} by NKT cells. These findings suggest that hepatic reperfusion injury is initiated by the CD1d-dependent activation of NKT cells, and the activation of these cells is inhibited by A2AR activation.

Abbreviations used: 8-SPT, 8-sulfophenyltheophylline; {alpha}-Gal-Cer, {alpha}-galactosylceramide; ADA, adenosine deaminase; ALT, alanine aminotransferase; ANOVA, analysis of variance; A2AR, adenosine A2A receptor; ATL146e, 4-{3-[6-amino-9- (5-ethylcarbamoyl-3,4-dihydroxy- tetrahydro-furan-2-yl)-9H- purin-2-yl]-prop-2-ynyl}- cyclohexanecarboxylic acid methyl ester; H&E, hematoxylin and eosin; IRI, ischemia reperfusion injury; iNKT, invariant NKT; ROS, reactive oxygen species; ZM241385, 4-(2-[7-amino-2-[2-furyl][1,2,4] triazolo[2,3-a][1,3,5]triazin-5-yl- amino]ethyl)phenol.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS